** Shares of 89Bio ETNB.O down 6.2% post-market to $8.44 as co looks to raise equity
** ETNB shares closed up ~26% at $9 on Mon, getting a boost after Akero Therapeutics AKRO.O said its lead drug, efruxifermin, showed it can help reverse scarring in patients with type of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH). AKRO shares ended session on Mon up 97.5% at $51.71
** After the bell, ETNB commences $250 mln offering comprised of stock and pre-funded warrants to fund its lead candidate, pegozafermin, to treat MASH
** Goldman Sachs, Leerink and BofA lead bookrunners
** Co has ~117.58 mln shares outstanding for ~$1.1 bln market cap, per LSEG
** ETNB shares, which have risen for past six sessions, up 15.1% YTD
** Separately, AKRO launched $300 mln stock offering after the bell
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.